Sarasota Memorial Hospital has earned the #1 spot among the world's WATCHMAN providers protecting people with atrial ...

The company expects its 2025 adjusted earnings to be in the range of $2.80 to $2.87 per share, above analysts' average ...

Boston Scientific apparently knows a good bet when it sees one. | That includes treating more than 200,000 patients with the irregular heartbeat known as atrial fibrillation—and the sum more than ...

Boston Scientific Corporation (NYSE: BSX) generated net sales of $4.561 billion during the fourth quarter of 2024 ...

Boston Scientific (NYSE: BSX) shares ticked up slightly before hours today on fourth-quarter results that beat the consensus ...

Boston Scientific Corporation (NYSE:BSX), a leading player in the medical technology sector, has been making waves in the industry with its innovative product pipeline and strong market performance.

Boston Scientific Corporation (NYSE:BSX), a leading player in the medical technology sector, has been making significant strides in recent years, positioning itself as a frontrunner in the industry.

Boston Scientific BSX is slated to report fourth ... with particular strength in its interventional cardiology therapies, WATCHMAN, cardiac rhythm management (CRM) and Peripheral Intervention ...

One of the standout products in Boston Scientific's portfolio is the Watchman FLX Left Atrial Appendage Closure (LAAC) device. Recent clinical trial results from the OPTION study demonstrated the ...